Alnylam Pharmace. buy The Goldman Sachs Group, Inc.
Start price
16.08.24
/
50%
€240.00
Target price
16.08.25
€336.33
Performance (%)
2.33%
Price
26.09.24
€245.60
Summary
This prediction is currently active. The BUY prediction by The_Goldman_Sachs_Gr shows slight gains of 2.33%. This prediction currently runs until 16.08.25. The prediction end date can be changed by The_Goldman_Sachs_Gr at any time. The_Goldman_Sachs_Gr has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Alnylam Pharmace. | -0.808% | -0.808% |
| iShares Core DAX® | 1.518% | 3.456% |
| iShares Nasdaq 100 | 1.240% | 2.983% |
| iShares Nikkei 225® | 2.808% | 2.743% |
| iShares S&P 500 | 0.403% | 2.187% |
Comments by The_Goldman_Sachs_Gr for this prediction
In the thread Alnylam Pharmace. diskutieren
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) was upgraded by analysts at The Goldman Sachs Group, Inc. from a "neutral" rating to a "buy" rating. They now have a $370.00 price target on the stock, up previously from $198.00.
Ratings data for ALNY provided by MarketBeat